FINWIRES · TerminalLIVE
FINWIRES

$NUVB

17 stories mentioning NUVBUpdated just now

Every FINWIRES story that references NUVB, newest first.

What are analysts saying about NUVB?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on NUVB?

Sectors

Sector Update: Healthcare Stocks Higher Late Afternoon

Healthcare stocks rose late Thursday afternoon, with the NYSE Healthcare Index adding 0.8% and the State Street Health Care Select Sector SPDR ETF (XLV) up 0.6%.The iShares Biotechnology ETF (IBB) climbed 2%.In corporate news, Pfizer's (PFE) Canadian operation Pfizer Canada ULC and BioNTech (BNTX) said Thursday that Health Canada has authorized XFG-adapted COMIRNATY COVID-19 vaccine for individuals aged 6 months and older. Pfizer shares added 0.5%, and BioNTech gained 2.8%.Medical Properties Trust (MPT) shares rose 8% in Thursday trading, a day after the company completed the sale of two Idaho hospital properties to affiliates of Intermountain Health for $413 million.Novo Nordisk (NVO) and Orbis Medicines struck an up to $1.4 billion licensing deal for the private company to develop oral drugs for cardiometabolic diseases. Novo will also make a "strategic investment" in Orbis. Separately, Novo said Thursday that the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended marketing authorization for Frehemgo or denecimig in the EU to treat haemophilia A, a bleeding disorder. Novo shares rose 3.9%.Nuvation Bio (NUVB) shares gained 5.3% after the company said the US Food and Drug Administration has approved its supplemental new drug application for taletrectinib to treat non-small cell lung cancer.

$BNTX$MPT$NUVB$NVO$PFE
Sectors

Sector Update: Healthcare Stocks Rise Thursday Afternoon

Healthcare stocks rose Thursday afternoon, with the NYSE Healthcare Index adding 0.5% and the State Street Health Care Select Sector SPDR ETF (XLV) up 0.4%.The iShares Biotechnology ETF (IBB) gained 1.8%.In corporate news, Novo Nordisk (NVO) and Orbis Medicines struck an up to $1.4 billion licensing deal for the private company to develop oral drugs for cardiometabolic diseases. Novo will also make a "strategic investment" in Orbis. Separately, Novo said Thursday that the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended marketing authorization for Frehemgo or denecimig in the EU to treat haemophilia A, a bleeding disorder. Novo shares rose 3.5%.Nuvation Bio (NUVB) shares gained 5.7% after the company said the US Food and Drug Administration has approved its supplemental new drug application for taletrectinib to treat non-small cell lung cancer.Astrana Health (ASTH) shares fell 3.5% after short seller GlassHouse Research published a report alleging that the company's profitability depends on its management's subjective estimates.

$ASTH$NUVB$NVO
Sectors

Sector Update: Healthcare Stocks Edge Higher Pre-Bell Thursday

Healthcare stocks were edging higher pre-bell Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.6% and the iShares Biotechnology ETF (IBB) advancing by 1.3%.Nuvation Bio (NUVB) stock was up more than 3% after the company said the FDA has approved its supplemental New Drug Application for IBTROZI (taletrectinib), a ROS1 inhibitor for locally advanced or metastatic ROS1-positive non-small cell lung cancer.Indivior Pharmaceuticals (INDV) shares were up more than 3% after the company said its board has declared a special cash dividend of $8.13 per share to holders of record as of Oct. 30.IDEXX Laboratories (IDXX) has expanded its Faecal Dx antigen testing platform in the UK to detect taeniid tapeworms, including Taenia and Echinococcus species, the company said. IDEXX Laboratories stock was up more than 1% premarket.

$IBB$IDXX$INDV$NUVB$XLV
Sectors

Sector Update: Healthcare

Healthcare stocks were edging higher pre-bell Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.6% and the iShares Biotechnology ETF (IBB) advancing by 1.3%.Nuvation Bio (NUVB) stock was up more than 3% after the company said the FDA has approved its supplemental New Drug Application for IBTROZI (taletrectinib), a ROS1 inhibitor for locally advanced or metastatic ROS1-positive non-small cell lung cancer.

$NUVB
Research

Cantor Fitzgerald Initiates Nuvation Bio at Overweight

Nuvation Bio (NUVB) has an average rating of buy and mean price target of $13.10, according to analysts polled by FactSet.

$NUVB
Sectors

Sector Update: Healthcare Stocks Fall Pre-Bell Thursday

Healthcare stocks were falling pre-bell Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) down 0.6% and the iShares Biotechnology ETF (IBB) declining by 0.9%.Ultragenyx Pharmaceutical (RARE) has received accelerated approval from the US Food and Drug Administration for Genglycos to treat glycogen storage disease type Ia, a rare genetic metabolic disorder due to an enzyme deficiency, the drugmaker said. Ultragenyx Pharmaceutical shares were up more than 7% premarket.Nuvation Bio (NUVB) stock was up more than 2% after the company said it has received US Food and Drug Administration fast-track designation for Safusidenib for the treatment IDH1-mutant glioma.AC Immune (ACIU) shares were up more than 2% after the company said preliminary results from a first-in-human Phase 1 trial of ACI-19764 showed the drug was safe and well tolerated in healthy volunteers.

$ACIU$IBB$NUVB$RARE$XLV
Research

JPMorgan Initiates Nuvation Bio at Overweight With $13 Price Target

Nuvation Bio (NUVB) has an average rating of buy and mean price target of $13.10, according to analysts polled by FactSet.

$NUVB
Wire

Nuvation Bio's Safusidenib Clinical Program, Ibtrozi Opportunity Create Favorable Setup, RBC Says

Nuvation Bio's (NUVB) leadership showed "significant excitement" around the Safusidenib clinical program, with strong recent data and new trials expected to demonstrate the company's commitment to the asset that could unlock over $3 billion in US sales, RBC Capital Markets said Wednesday.Management remains committed to Safusidenib's development and targeting all parts of the glioma pie, and enrollment in Sigma is progressing steadily, with the team hoping for data in 2027, the note added.The company reiterated its Ibtrozi strategy of focusing on first-line treatment patients, which should translate into higher revenues in the back half of the year and allow Nuvation to meet consensus sales estimates, according to the note. RBC estimates $128 million in 2026 sales.Nuvation Bio could potentially be an acquisition target, and any deal would need to appropriately value both the Ibtrozi commercial opportunity and the Safusidenib pipeline, the brokerage said.RBC has an outperform, speculative risk rating on Nuvation Bio with a price target of $19.Price: $6.21, Change: $-0.23, Percent Change: -3.50%

$NUVB
Sectors

Sector Update: Healthcare Stocks Fall Late Afternoon

Healthcare stocks declined late Monday afternoon, with the NYSE Healthcare Index shedding 1.1% and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.8%.The iShares Biotechnology ETF (IBB) fell 1.1%.In corporate news, Eli Lilly (LLY) has indicated an interest in buying shares at Scribe Therapeutics' initial public offering sufficient to raise its stake to as much as 10.9% following the offering and a concurrent private placement, Scribe said in a regulatory filing on Monday. Lilly shares were falling 2.2%.Tempus AI (TEM) agreed to acquire Personalis (PSNL) in a deal with a total enterprise value of $1.5 billion. Tempus AI shares fell 7.3%, and Personalis dropped 14%.Nuvation Bio (NUVB) shares jumped past 8% after it said Monday that follow-up data from a phase 2 trial of safusidenib in people with chemotherapy and radiotherapy-naive grade 2 IDH1-mutant glioma showed "durable" efficacy, with objective response rate of 51.9% and 36-month progression-free survival rate of 79.1%.Bristol-Myers Squibb (BMY) said Monday that it is expanding its partnership with Nvidia (NVDA) to build an AI factory dedicated to pharmaceutical research and development. Bristol-Myers Squibb shares were shedding 0.9%.

$BMY$LLY$NUVB$PSNL$TEM
Sectors

Sector Update: Healthcare

Healthcare stocks declined late Monday afternoon, with the NYSE Healthcare Index shedding 1.1% and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.8%.The iShares Biotechnology ETF (IBB) fell 1.1%.In corporate news, Nuvation Bio (NUVB) shares jumped past 8% after it said Monday that follow-up data from a phase 2 trial of safusidenib in people with chemotherapy and radiotherapy-naive grade 2 IDH1-mutant glioma showed "durable" efficacy, with objective response rate of 51.9% and 36-month progression-free survival rate of 79.1%.

$NUVB
Wire

Nuvation Bio's Safusidenib Data Support Broader Glioma Opportunity, Wedbush Says

Nuvation Bio's (NUVB) updated phase 2 data for safusidenib in Japanese patients with grade 2 IDH1-mutant glioma strengthens the drug's long-term potential, supported by improved objective response rates, durable progression-free survival and a favorable safety profile, Wedbush Securities said in a Monday note.The brokerage noted that Nuvation plans to launch a pivotal ex-US phase 3 trial in newly diagnosed grade 2 IDH1-mutant glioma patients and a phase 2 study in patients whose disease has progressed after prior treatment with vorasidenib.The expanded development plan could widen safusidenib's market potential beyond the pivotal SIGMA study by targeting both treatment-naive and post-vorasidenib patients, with initial results from an exploratory post-surgical grade 3 oligodendroglioma cohort expected in 2027, the brokerage added.Wedbush maintained an outperform rating on the stock with an $11 price target.Nuvation Bio shares were up 11% in Monday trading.Price: $6.46, Change: $+0.66, Percent Change: +11.29%

$NUVB
Wire

Nuvation Bio Faces More Predictable Growth Supported by Ibtrozi Frontline Adoption, Wedbush Says

Nuvation Bio's (NUVB) Q2 results will be an important checkpoint for Ibtrozi's commercial launch as it transitions to a "more durable, frontline-driven growth profile," with investors eyeing revenue variability, Wedbush said in a note Tuesday.The brokerage said it expects quarterly revenue to become "materially more predictable" over the coming quarters, as the mix continues to skew toward treatment-naive patients with median duration of response of about four years.The firm forecasts Q2 Ibtrozi revenue of $22.2 million, up 20% sequentially, and full-year 2026 revenue of $122.3 million. Wedbush also noted that safusidenib remains an "underappreciated long-term value driver."The firm reiterated its outperform rating on the stock with $11 price target.Price: $5.74, Change: $+0.13, Percent Change: +2.23%

$NUVB
Commodities

Correction: Exchange-Traded Funds, Equity Futures Decline Pre-Bell Friday as Investors Shift Focus From Middle East to Technology Stocks

(Corrects the third paragraph to state that May advance trade deficit widened.)The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.7%, and the actively traded Invesco QQQ Trust (QQQ) retreated 1.6% in Friday's premarket activity, as investors shifted their focus from the US-Iran conflict in the Middle East to technology stocks.US stock futures were also lower, with S&P 500 Index futures down 0.5%, Dow Jones Industrial Average futures slipping 0.2%, and Nasdaq futures retreating 1.4% before the start of regular trading.The US advance international trade in goods deficit widened to $105.76 billion in May from $83.01 billion in April, according to data released by the US Census Bureau.June's final University of Michigan consumer sentiment report is slated for a 10 am ET release, followed by the weekly Baker Hughes oil-and-gas rig count at 1 pm ET.Federal Reserve Bank of Minneapolis President Neel Kashkari is scheduled to speak on Friday.In premarket action, bitcoin was down 0.3%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was down 0.2%, ProShares Ether ETF (EETH) declined by 1.3%, and Bitcoin & Ether Market Cap Weight ETF (BETH) lost 0.01%.Power Play:ConsumerThe State Street Consumer Staples Select Sector SPDR ETF (XLP) was up 0.5%, the Vanguard Consumer Staples Index Fund ETF Shares (VDC) was down 0.8%, and the iShares US Consumer Staples ETF (IYK) was 0.1% lower. The State Street Consumer Discretionary Select Sector SPDR ETF (XLY) lost 0.1%. The VanEck Retail ETF (RTH) was inactive, while the State Street SPDR S&P Retail ETF (XRT) was flat.Trip.com (TCOM) shares were down more than 3% pre-bell as multiple analyst price target cuts followed the company's Q1 earnings announcement.Winners and Losers:FinancialThe State Street Financial Select Sector SPDR ETF (XLF) advanced 0.3%. Direxion Daily Financial Bull 3X Shares (FAS) was up 0.6%, while its bearish counterpart, Direxion Daily Financial Bear 3X Shares (FAZ), was 0.2% lower.HIVE Digital Technologies (HIVE) shares traded down 6.1% in early hours activity after the company priced an offering of $115 million worth of 0% exchangeable senior notes due 2031 in a private offering.HealthcareThe State Street Health Care Select Sector SPDR ETF (XLV) advanced 0.03%, the Vanguard Health Care Index Fund (VHT) was up 1.1%, while the iShares US Healthcare ETF (IYH) rose 0.5%. The iShares Biotechnology ETF (IBB) was 0.1% lower.Nuvation Bio (NUVB) stock was down nearly 1% premarket, extending losses from the previous day's 10% fall. The company said late Thursday it priced an underwritten offering of $250 million of 0.75% convertible senior notes due in 2032.EnergyThe iShares US Energy ETF (IYE) was marginally higher, while the State Street Energy Select Sector SPDR ETF (XLE) was down by 0.5%.Equinor (EQNR) stock was down nearly 2% before market open after the company said it is ending its offshore wind business activities in Japan and shutting its Tokyo office by the end of the year.IndustrialThe State Street Industrial Select Sector SPDR ETF (XLI) retreated by 0.2%, while the Vanguard Industrials Index Fund (VIS) gained by 0.2% and the iShares US Industrials ETF (IYJ) was flat.AerCap (AER) stock was up more than 2% before the opening bell after the company said it delivered the first of three Airbus A321neo aircraft to Azerbaijan Airlines.TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) retreated 2.1%, and the iShares US Technology ETF (IYW) was 1.4% lower, while the iShares Expanded Tech Sector ETF (IGM) was down 2%. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) declined by 2.9%, while the iShares Semiconductor ETF (SOXX) fell by 4.3%.Microsoft (MSFT) shares were up 1.4% in premarket activity after closing the prior day with a 3.5% fall. The Italian Competition Authority said the company faces a formal regulatory investigation into whether it engaged in deceptive marketing during a recent price increase for Microsoft 365.CommoditiesFront-month US West Texas Intermediate crude oil fell by 3.1% to $69.70 per barrel on the New York Mercantile Exchange. Natural gas gained by 2.9% to $3.44 per 1 million British Thermal Units. The United States Oil Fund (USO) declined by 3.2%, while the United States Natural Gas Fund (UNG) was 2.5% higher.Gold futures for July were up by 0.4% to $4,063.80 an ounce on the Comex. Silver futures gained by 0.1% to $58.83 an ounce. SPDR Gold Shares (GLD) advanced by 0.4%, and the iShares Silver Trust (SLV) was 0.5% higher.

Dow JonesNasdaq CompositeS&P 500$AER$BETH$BITO$EEM$EETH$EQNR$EXI$FAS$FAZ$GLD$HIVE$IBB$IGM$IGV$IPK$IVV$IWM$IYE$IYH$IYJ$IYK$IYW$MSFT$NUVB$PMR$QQQ$RTH$SLV$SOXX$SPY$TCOM$UNG$USO$VDC$VHT$VIS$XLE$XLF$XLI$XLK$XLP$XLV$XLY$XRT$XSD
Commodities

Exchange-Traded Funds, Equity Futures Decline Pre-Bell Friday as Investors Shift Focus From Middle East to Technology Stocks

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.7%, and the actively traded Invesco QQQ Trust (QQQ) retreated 1.6% in Friday's premarket activity, as investors shifted their focus from the US-Iran conflict in the Middle East to technology stocks.US stock futures were also lower, with S&P 500 Index futures down 0.5%, Dow Jones Industrial Average futures slipping 0.2%, and Nasdaq futures retreating 1.4% before the start of regular trading.The US advance international trade in goods deficit narrowed to $105.76 billion in May from $83.01 billion in April, according to data released by the US Census Bureau.June's final University of Michigan consumer sentiment report is slated for a 10 am ET release, followed by the weekly Baker Hughes oil-and-gas rig count at 1 pm ET.Federal Reserve Bank of Minneapolis President Neel Kashkari is scheduled to speak on Friday.In premarket action, bitcoin was down 0.3%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was down 0.2%, ProShares Ether ETF (EETH) declined by 1.3%, and Bitcoin & Ether Market Cap Weight ETF (BETH) lost 0.01%.Power Play:ConsumerThe State Street Consumer Staples Select Sector SPDR ETF (XLP) was up 0.5%, the Vanguard Consumer Staples Index Fund ETF Shares (VDC) was down 0.8%, and the iShares US Consumer Staples ETF (IYK) was 0.1% lower. The State Street Consumer Discretionary Select Sector SPDR ETF (XLY) lost 0.1%. The VanEck Retail ETF (RTH) was inactive, while the State Street SPDR S&P Retail ETF (XRT) was flat.Trip.com (TCOM) shares were down more than 3% pre-bell as multiple analyst price target cuts followed the company's Q1 earnings announcement.Winners and Losers:FinancialThe State Street Financial Select Sector SPDR ETF (XLF) advanced 0.3%. Direxion Daily Financial Bull 3X Shares (FAS) was up 0.6%, while its bearish counterpart, Direxion Daily Financial Bear 3X Shares (FAZ), was 0.2% lower.HIVE Digital Technologies (HIVE) shares traded down 6.1% in early hours activity after the company priced an offering of $115 million worth of 0% exchangeable senior notes due 2031 in a private offering.Health CareThe State Street Health Care Select Sector SPDR ETF (XLV) advanced 0.03%, the Vanguard Health Care Index Fund (VHT) was up 1.1%, while the iShares US Healthcare ETF (IYH) rose 0.5%. The iShares Biotechnology ETF (IBB) was 0.1% lower.Nuvation Bio (NUVB) stock was down nearly 1% premarket, extending losses from the previous day's 10% fall. The company said late Thursday it priced an underwritten offering of $250 million of 0.75% convertible senior notes due in 2032.EnergyThe iShares US Energy ETF (IYE) was marginally higher, while the State Street Energy Select Sector SPDR ETF (XLE) was down by 0.5%.Equinor (EQNR) stock was down nearly 2% before market open after the company said it is ending its offshore wind business activities in Japan and shutting its Tokyo office by the end of the year.IndustrialThe State Street Industrial Select Sector SPDR ETF (XLI) retreated by 0.2%, while the Vanguard Industrials Index Fund (VIS) gained by 0.2% and the iShares US Industrials ETF (IYJ) was flat.AerCap (AER) stock was up more than 2% before the opening bell after the company said it delivered the first of three Airbus A321neo aircraft to Azerbaijan Airlines.TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) retreated 2.1%, and the iShares US Technology ETF (IYW) was 1.4% lower, while the iShares Expanded Tech Sector ETF (IGM) was down 2%. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) declined by 2.9%, while the iShares Semiconductor ETF (SOXX) fell by 4.3%.Microsoft (MSFT) shares were up 1.4% in premarket activity after closing the prior day with a 3.5% fall. The Italian Competition Authority said the company faces a formal regulatory investigation into whether it engaged in deceptive marketing during a recent price increase for Microsoft 365.CommoditiesFront-month US West Texas Intermediate crude oil fell by 3.1% to $69.70 per barrel on the New York Mercantile Exchange. Natural gas gained by 2.9% to $3.44 per 1 million British Thermal Units. The United States Oil Fund (USO) declined by 3.2%, while the United States Natural Gas Fund (UNG) was 2.5% higher.Gold futures for July were up by 0.4% to $4,063.80 an ounce on the Comex. Silver futures gained by 0.1% to $58.83 an ounce. SPDR Gold Shares (GLD) advanced by 0.4%, and the iShares Silver Trust (SLV) was 0.5% higher.

Dow JonesNasdaq CompositeS&P 500$AER$BETH$BITO$EEM$EETH$EQNR$EXI$FAS$FAZ$GLD$HIVE$IBB$IGM$IGV$IPK$IVV$IWM$IYE$IYH$IYJ$IYK$IYW$MSFT$NUVB$PMR$QQQ$RTH$SLV$SOXX$SPY$TCOM$UNG$USO$VDC$VHT$VIS$XLE$XLF$XLI$XLK$XLP$XLV$XLY$XRT$XSD
Wire

Nuvation Bio to Launch $200 Million Senior Notes Offering; Shares Fall Pre-Bell

Nuvation Bio (NUVB) said Thursday it plans to offer $200 million worth of convertible senior notes due 2032 in an underwritten offering.The company said it will grant the underwriters the right to purchase up to an additional $30 million of notes to cover any overallotments.Net proceeds from the offering will be used to pay the cost of capped call transactions, repay all obligations under its senior secured loan agreement, and for general corporate purposes, such as working capital, operating expenses, capital expenditures and general and administrative expenses.Shares of Nuvation Bio declined more than 9% in recent pre-bell activity Thursday.Price: $5.83, Change: $-0.63, Percent Change: -9.75%

$NUVB
Insider Trading

Nuvation Bio Insider Sold Shares Worth $251,000, According to a Recent SEC Filing

Dongfang Liu, Chief Medical Officer, on April 17, 2026, sold 50,000 shares in Nuvation Bio (NUVB) for $251,000. Following the Form 4 filing with the SEC, Liu has control over a total of 18,000 Class A common shares of the company, with 18,000 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1811063/000193791526000004/xslF345X05/form4-04212026_080401.xml

$NUVB
Wire

Nuvation Bio's Ibtrozi Gains Frontline Momentum Ahead of Key Q1 Print, Wedbush Says

Nuvation Bio (NUVB) is approaching its Q1 earnings as an important checkpoint for the commercial trajectory of its ROS1 inhibitor Ibtrozi, with early signs of accelerating uptake and potential expansion into earlier lines of therapy, Wedbush Securities said in a Thursday note.According to the report, Ibtrozi generated $15.7 million in Q4 2025 revenue with 216 new patient starts, bringing total starts to 432 since launch.Wedbush said a significant share of those starts has occurred in later-line settings, where discontinuation rates are higher and could create a temporary gap in revenue growth over the next one to two quarters.Wedbush said physician survey data indicate Ibtrozi could become the fastest-growing ROS1 inhibitor in the first-line setting, with share rising from about 12% to roughly 20% over the next six months.The firm said prescribing intent remains broad across treatment settings despite limited commercial engagement to date, highlighting an opportunity for increased sales outreach.The brokerage said IQVIA retail sales and prescription data indicate continued sequential growth, though data limitations prevent precise extrapolation.It added that earlier-line use is expected to reduce discontinuation rates and allow revenue growth to more closely track new patient starts over time.Wedbush maintained an outperform rating on the stock with a price target of $11.Shares of Nuvation Bio were down 2.8% in Thursday trading.Price: $4.69, Change: $-0.13, Percent Change: -2.70%

$NUVB

Track with the FINWIRES app suite